Transcriptomics-Guided Multi-Cohort Machine Learning for Alzheimer’s Disease Diagnosis

Why It Matters

The high predictive performance and external robustness suggest a viable, interpretable tool for early AD detection, potentially accelerating clinical decision‑making and therapeutic trials.

Key Takeaways

• Ensemble of GBM and GLMNET achieved AUC 0.97 in internal testing.
• Cross‑validation AUCs ranged 0.84‑0.88 across six classifiers.
• 30 DEGs identified; 20 formed key predictive signature.
• COL27A1, LINC02937, TEPSIN top dysregulated genes in AD.
• External cohorts showed mean AUC 0.89, confirming generalizability.

Pulse Analysis

Alzheimer’s disease remains the leading cause of dementia, yet reliable early‑diagnostic biomarkers are scarce. Recent advances in high‑throughput transcriptomics have opened a pathway to capture disease‑specific molecular signatures directly from brain tissue. By integrating these data with sophisticated machine‑learning algorithms, researchers can move beyond traditional imaging or cognitive tests, offering a molecular lens that may detect pathological changes before clinical symptoms manifest.

The study leveraged four public GEO datasets, extracting 30 differentially expressed genes that distinguished Alzheimer’s patients from controls. Six supervised classifiers—including GLMNET, SVM, Random Forest, and Gradient Boosting—were trained on 231 samples, delivering cross‑validation AUCs between 0.84 and 0.88. Notably, the GBM model achieved an internal‑test AUC of 0.962, while a weighted ensemble of GBM and GLMNET reached 0.97, underscoring the power of model combination. External validation across independent cohorts preserved a mean AUC of 0.89, confirming the pipeline’s generalizability and resilience to dataset variability.

Beyond performance metrics, the analysis identified a concise panel of 20 predictive genes, with COL27A1, LINC02937, and TEPSIN emerging as top dysregulated markers. These genes provide tangible targets for diagnostic assay development and may illuminate novel therapeutic pathways. As the field pushes toward precision neurology, such interpretable, high‑accuracy models could be integrated into clinical workflows, enabling earlier intervention and more efficient enrollment in clinical trials. Continued validation in larger, diverse populations will be essential to translate these findings into routine care.